Sara Nochur
Director/Board Member bij MARINUS PHARMACEUTICALS, INC.
Vermogen: 57 404 $ op 31-03-2024
Profiel
Saraswathy V.
Nochur is currently the Chairman at Hospitality Homes and an Independent Director at Marinus Pharmaceuticals, Inc. She is also a Director at Biomedical Sciences Careers Program, Inc. and the Chief Diversity, Equity & Inclusion Officer at Alnylam Pharmaceuticals, Inc. Her former positions include being a Director of New Product Development at DynaGen, Inc., Director of Product Development & Regulatory Affairs at Ischemix, Inc., Independent Director at Decibel Therapeutics, Inc. from 2021 to 2023, Vice President of Regulatory Affairs at The Medicines Co., and COO and VP of Product Development & Regulatory Affairs at Biotrack, Inc. Dr. Nochur holds a doctorate degree from the Massachusetts Institute of Technology and undergraduate and graduate degrees from the University of Mumbai.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-04-2024 | 6 350 ( 0.01% ) | 57 404 $ | 31-03-2024 |
Actieve functies van Sara Nochur
| Bedrijven | Functie | Begin |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-01-2021 |
| MARINUS PHARMACEUTICALS, INC. | Director/Board Member | 22-03-2021 |
| Hospitality Homes | Chairman | 01-01-2021 |
| Biomedical Sciences Careers Program, Inc. | Director/Board Member | - |
Eerdere bekende functies van Sara Nochur
| Bedrijven | Functie | Einde |
|---|---|---|
| DECIBEL THERAPEUTICS, INC. | Director/Board Member | 22-09-2023 |
| THE MEDICINES COMPANY | General Counsel | - |
| Biotrack, Inc. | Chief Operating Officer | - |
| DynaGen, Inc. | Corporate Officer/Principal | - |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | General Counsel | - |
Opleiding van Sara Nochur
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Mumbai | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
| DynaGen, Inc. | Health Technology |
| Biomedical Sciences Careers Program, Inc. | |
| Biotrack, Inc. | |
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
| Hospitality Homes |
